Weil Company’s Bristol-Myers Squibb BMY Stock Holding History

Weil Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,100	Closed	-$56K	–	143
2019 Q3	$56K	Buy	+1,100	New	+$51.7K	0.04%	186

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Weil Company's BMY Position: Q4 2019 in Review

Weil Company sold out of Bristol-Myers Squibb (BMY) in Q4 2019, closing a stake of 1,100 shares — an estimated $56K sold.

Weil Company first reported a position in BMY in Q3 2019 and held it in 1 quarter. The position peaked at $56K in Q3 2019. 2,217 funds tracked by Wall St. Rank hold BMY as of Q4 2019.

Weil Company reported no remaining Bristol-Myers Squibb position as of Q4 2019 after selling out during the quarter.
Weil Company sold 1,100 Bristol-Myers Squibb shares in Q4 2019, an estimated $56K.
Weil Company first reported a position in Bristol-Myers Squibb in Q3 2019 and held it in 1 quarter.
Weil Company's Bristol-Myers Squibb position peaked at $56K in Q3 2019.
2,217 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.